← Leaderboards
Jeremy D Rubinstein
Cincinnati Childrens Hosp Med Ctr
$1,322,748
Attributed
$1,322,748
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $676.5K · FY2024–25$1M$750K$500K$250K$0
'24
'25
Funding mix
By agency
NIH$1,322,748 · 1
By mechanism
R01$1,322,748 · 1
Top collaborators
No co-investigators on record.
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- Susanne Irmtraud Wells$12,656,530
- Benjamin Lewis Laskin$2,868,869
- Jason T Blackard$10,171,334
- Rhonda D Cardin$2,411,196
- Daniel Lucas$9,614,171
Others in their field
Other Rising Stars on “Allogenic”
- Guang-Shing Cheng · Fred Hutchinson Cancer Center$3,067,611
- Kellie Bickel · Twinstrand Biosciences, Inc.$2,555,383
- Hunter Ramsdell Gibbons · Luminary Therapeutics, Inc.$1,962,052
- Riccardo Gottardi · Children'S Hosp Of Philadelphia$1,873,073
- Sayan Dasgupta · University Of Washington$1,836,282
- Saad J. Kenderian · Mayo Clinic Rochester$1,822,469
Research focus
AllogenicAntigen PresentationAntigensAnti-Viral AgentsAreaBk VirusBloodCell BankCell CountCell LineCellsCell TherapyChildChildhoodClinical TrialsClone CellsCollaborationsComplicationConserved SequenceCryopreservationCytomegalovirusCytotoxic T-LymphocytesDefectAdenoviruses
Grant awards (2)
Allogeneic virus-specific T-cell therapy after hematopoietic stem cell transplant: determinants of treatment success and failure$646,249
R01 · FY2025 · HL · contact PI
Allogeneic virus-specific T-cell therapy after hematopoietic stem cell transplant: determinants of treatment success and failure$676,499
R01 · FY2024 · HL · contact PI